Stable Tryptamine Oral Films with Acidic pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral film dosage forms face challenges in stability, effective dosage, mouth feel, taste, and shelf life, particularly for less potent active ingredients like tryptamines, with issues of inconsistent stability and bioavailability, and difficulty in penetrating the mucosa for systemic absorption.
Innovation Solution
The formulation includes psilocybin analogues with added phosphoric acid or other inorganic acids to adjust pH, a polymeric matrix, plasticizers, and stabilizers like phosphoric acid, citric acid, and antioxidants, along with a protective backing layer to enhance stability and mucosal penetration, ensuring high stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If traditional oral film formulations are used for tryptamines, then the film can be administered orally, but the stability and shelf life are insufficient
Solution Approach 1:
The patent adjusts the pH of the oral film formulation to an acidic range (pH 2-5) using phosphoric acid or other inorganic acids. This parameter change stabilizes tryptamines by preventing their degradation through oxidation and hydrolysis, thereby improving both stability and extending shelf life without requiring complex stabilizing additives
Solution Approach 2:
The patent combines tryptamines with a polymeric matrix and inorganic acids to create a composite oral film formulation. This composite structure provides a stable environment for the tryptamine while maintaining film integrity, solubility, and extended shelf life through the synergistic interaction of components
2Quantity of substance
If less potent active ingredients like tryptamines are used, then the dosage can be adjusted, but the bioavailability is insufficient
Solution Approach 1:
The patent formulates the oral film with a low pH (2-5) environment which enhances the solubility and stability of tryptamines. This parameter optimization ensures consistent bioavailability by preventing premature degradation and maintaining the active ingredient in a bioavailable state until absorption
Solution Approach 2:
The patent pre-stabilizes the tryptamine in the acidic film matrix before administration. This preliminary stabilization prevents degradation during storage and handling, ensuring that the full dosage reaches the absorption site with consistent bioavailability
3Ease of operation
If the oral film is designed for rapid dissolution, then it can be administered easily, but the penetration and crossing of the mucosa layer is insufficient
Solution Approach 1:
The patent optimizes the film's pH (2-5) and composition to balance dissolution rate with mucosal penetration. The acidic environment promotes rapid dissolution for easy administration while the stabilized tryptamine maintains sufficient concentration and stability to penetrate the mucosa effectively for systemic absorption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oral dissolvable films maintain high stability under accelerated conditions, provide effective dosing, and enhance bioavailability by direct mucosal absorption, improving therapeutic effects for conditions like depression and anxiety.
Implementation Method 1
phosphoric acid or other inorganic acids or a combination thereof can be added to the psilocybin film oral dosage forms disclosed herein in amounts effective to adjust the pH within a range of from 1.5 to 5.0
Implementation Method 2
there is a need for an increased penetration and crossing of the mucosa layer by active ingredients, thereby allowing active ingredients to enter into systemic circulation
Data Source
AI summary
Pharmaceutical compositions with tryptamines having enhanced active stability properties are described.